A Prospective Phase II Clinical Trial Evaluating the Efficacy and the Safety of Tyrosine Kinase Inhibitors Withdrawal After a Previous Two-step Dose Reduction in Patients With Chronic Myeloid Leukemia in Deep Molecular Remission
Latest Information Update: 28 Nov 2024
At a glance
- Drugs Dasatinib (Primary) ; Imatinib (Primary) ; Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms HALF
Most Recent Events
- 04 Jul 2023 Planned End Date changed from 1 Dec 2025 to 1 Jun 2026.
- 04 Jul 2023 Planned primary completion date changed from 1 Dec 2025 to 1 Jun 2026.
- 04 Jul 2023 Status changed from recruiting to active, no longer recruiting.